Nind A P, Matthews N, Pihl E A, Rolland J M, Nairn R C
Br J Cancer. 1975 Jun;31(6):620-9. doi: 10.1038/bjc.1975.108.
Serum inhibition of autochthonous lymphocyte cytotoxicity for tumour cells has been studied in 112 cases of colonic carcinoma. Addition of patient's serum to the lymphocyte tumour cell reaction mixture resulted in decreased cytotoxic reactivity of lymphocytes from 8 of 39 cytotoxic positive cases. It was also shown that sera could inhibit if separately preincubated with the lymphocytes (4 cases) or the target cells (2 cases). A tumour antigen preparation inhibited only when incubated with the lymphocytes. Inhibition by serum or antigen appeared to be specific for colon carcinoma. Four cases were specially studied to determine the mode of lymphocyte killing of tumour cells: in 3 it was mediated largely if not entirely by T lymphocytes, and in the fourth by both T and non-T cells. The findings support the view that T lymphocytes lose their anti-tumour reactivity in vivo in the presence of circulating antigen or antigen-antibody complexes such as would occur with progressive tumour growth.
在112例结肠癌患者中研究了血清对自身淋巴细胞针对肿瘤细胞的细胞毒性的抑制作用。将患者血清加入淋巴细胞肿瘤细胞反应混合物中，导致39例细胞毒性阳性病例中的8例淋巴细胞的细胞毒性反应性降低。还表明，如果血清分别与淋巴细胞（4例）或靶细胞（2例）预孵育，血清也可产生抑制作用。肿瘤抗原制剂仅在与淋巴细胞一起孵育时才产生抑制作用。血清或抗原的抑制作用似乎对结肠癌具有特异性。对4例患者进行了专门研究以确定淋巴细胞杀伤肿瘤细胞的方式：在3例中，杀伤作用如果不是完全由T淋巴细胞介导，也是主要由T淋巴细胞介导，而在第4例中则由T细胞和非T细胞共同介导。这些发现支持这样一种观点，即在存在循环抗原或抗原 - 抗体复合物（如在肿瘤进行性生长时会出现的情况）的情况下，T淋巴细胞在体内会失去其抗肿瘤反应性。
